Gilead Sciences has signed a five-year agreement extension with Cognizant to advance its DevOps environment and support the deployment of agentic AI tools across designated technology initiatives.

CSL and Alentis will work together to progress antifibrotic drug, lixudebart across multiple rare kidney and liver diseases.

AstraZeneca has opened a new global strategic R&D facility in Massachusetts, US, as part of an investment of more than $1bn in the state.

The US FDA has approved an expanded indication for Lilly's Jaypirca as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion.

The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, as pharma explores its role on treating ophthalmic conditions.

The US FDA has expanded the approved indication for BMS' Camzyos to treat symptomatic oHCM in adults and paediatric patients weighing at least 30 kg.

Summit is currently developing Ivonescimab in combination with other drugs across several types of solid tumours.

Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.

AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and ADCs across multiple tumour types.

Unlike other therapies in this class, Abogen’s ABO2203 is designed to produce a T-cell engager protein in vivo through an mRNA-encoded system.

Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their pipeline horizon – the companies have agreed to expand ...

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.